NICE recommends Sobi’s Kineret for first-line use in Still’s disease
Biologic therapy approved to treat systemic juvenile idiopathic arthritis and adult-onset Still’s disease
Read More
Tag: Kineret
Four new therapies to be funded by NHS Scotland
The Scottish Medicines Consortium has endorsed NHS funding for four therapies, offering new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis.
Read More
Sobi launches Kineret for AOSD, SJIA
Sobi UK and Ireland has announced the launch of Kineret across the country offering a new treatment option for Adult Onset Stills Disease (AOSD) and Systemic-Onset Juvenile Idiopathic Arthritis (SJIA).
Read More
EU regulators expand reach of Sobi’s Kineret
European regulators have expanded the scope of Sobi’s Kineret to include the treatment of Still’s disease, a rare, systemic, multi-organ, auto-inflammatory disorder that affects around 25,000 children and adults in the EU.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
